Aytu BioPharma Statistics
Total Valuation
Aytu BioPharma has a market cap or net worth of $28.91 million. The enterprise value is $19.92 million.
Important Dates
The last earnings date was Monday, November 16, 2026, after market close.
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aytu BioPharma has 10.87 million shares outstanding. The number of shares has increased by 107.64% in one year.
| Current Share Class | 10.87M |
| Shares Outstanding | 10.87M |
| Shares Change (YoY) | +107.64% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 5.14% |
| Owned by Institutions (%) | 12.70% |
| Float | 7.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.49 |
| Forward PS | 0.39 |
| PB Ratio | 0.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.04 |
| P/OCF Ratio | 7.98 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 5.54 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.07 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | 4.59 |
| Interest Coverage | -6.01 |
Financial Efficiency
Return on equity (ROE) is -73.44% and return on invested capital (ROIC) is -51.73%.
| Return on Equity (ROE) | -73.44% |
| Return on Assets (ROA) | -17.93% |
| Return on Invested Capital (ROIC) | -51.73% |
| Return on Capital Employed (ROCE) | -23.43% |
| Weighted Average Cost of Capital (WACC) | 6.57% |
| Revenue Per Employee | $770,053 |
| Profits Per Employee | -$264,447 |
| Employee Count | 76 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 2.66 |
Taxes
In the past 12 months, Aytu BioPharma has paid $21,000 in taxes.
| Income Tax | 21,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.00% in the last 52 weeks. The beta is 0.22, so Aytu BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +33.00% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.28 |
| Relative Strength Index (RSI) | 79.51 |
| Average Volume (20 Days) | 375,678 |
Short Selling Information
The latest short interest is 301,698, so 2.78% of the outstanding shares have been sold short.
| Short Interest | 301,698 |
| Short Previous Month | 328,872 |
| Short % of Shares Out | 2.78% |
| Short % of Float | 3.95% |
| Short Ratio (days to cover) | 11.31 |
Income Statement
In the last 12 months, Aytu BioPharma had revenue of $58.52 million and -$20.10 million in losses. Loss per share was -$1.36.
| Revenue | 58.52M |
| Gross Profit | 37.07M |
| Operating Income | -10.74M |
| Pretax Income | -20.08M |
| Net Income | -20.10M |
| EBITDA | -6.49M |
| EBIT | -10.74M |
| Loss Per Share | -$1.36 |
Full Income Statement Balance Sheet
The company has $25.49 million in cash and $16.51 million in debt, with a net cash position of $8.99 million or $0.83 per share.
| Cash & Cash Equivalents | 25.49M |
| Total Debt | 16.51M |
| Net Cash | 8.99M |
| Net Cash Per Share | $0.83 |
| Equity (Book Value) | 31.56M |
| Book Value Per Share | 2.90 |
| Working Capital | 3.84M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $3.62 million and capital expenditures -$29,000, giving a free cash flow of $3.60 million.
| Operating Cash Flow | 3.62M |
| Capital Expenditures | -29,000 |
| Depreciation & Amortization | 4.25M |
| Net Borrowing | -10.73M |
| Free Cash Flow | 3.60M |
| FCF Per Share | $0.33 |
Full Cash Flow Statement Margins
Gross margin is 63.34%, with operating and profit margins of -18.35% and -34.34%.
| Gross Margin | 63.34% |
| Operating Margin | -18.35% |
| Pretax Margin | -34.31% |
| Profit Margin | -34.34% |
| EBITDA Margin | -11.10% |
| EBIT Margin | -18.35% |
| FCF Margin | 6.14% |
Dividends & Yields
Aytu BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -107.64% |
| Shareholder Yield | -107.64% |
| Earnings Yield | -51.09% |
| FCF Yield | 12.44% |
Analyst Forecast
The average price target for Aytu BioPharma is $8.85, which is 232.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.85 |
| Price Target Difference | 232.71% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 26.39% |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 6, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |